Lexicon Pharmaceuticals (LXRX) Current Assets (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Current Assets data on file, last reported at $186.0 million in Q1 2026.

• On a quarterly basis, Current Assets fell 24.32% year-over-year to $186.0 million in Q1 2026; TTM through Mar 2026 was $186.0 million, a 24.32% decrease from a year earlier, with the FY2025 full-year figure at $101.9 million, down 58.61% from the prior year.
• Current Assets for Q1 2026 stood at $186.0 million, up from $101.9 million in the prior quarter.
• Over the last five years, Current Assets for LXRX reached as high as $364.6 million in Q1 2024 and fell as low as $64.9 million in Q2 2022.
• Historically, Current Assets has averaged $188.7 million across 5 years, with a median of $176.5 million in 2023.
• Across the five-year window, Current Assets surged 306.36% in 2023 and plunged 58.61% in 2025, its largest moves.
• Year by year, Current Assets stood at $140.9 million in 2022, then advanced by 25.33% to $176.5 million in 2023, then jumped by 39.45% to $246.2 million in 2024, then tumbled by 58.61% to $101.9 million in 2025, then soared by 82.57% to $186.0 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $186.0 million in Q1 2026, $101.9 million in Q4 2025, and $122.5 million in Q3 2025.